Navigation Links
Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
Date:12/8/2008

Generic Erosion Will Reduce Sales of Schering-Plough's Temodar/Temodal, the Current Market Leader, According to a New Report from Decision Resources

WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the approval of agents to treat glioma, most notably Roche/Genentech/Chugai's Avastin, will drive market sales to more than double to more than $1.8 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Glioma finds that sales of Avastin, which is already used off-label to treat relapsed glioma and is in development for treating both relapsed and newly-diagnosed patients, will account for more than half of the total market in 2017. Sales of Schering-Plough's Temodar/Temodal, the current leading agent for glioma in both patient share and market share, will fall significantly from 2007 to 2017, owing to generic erosion.

According to the report, in addition to Avastin, the launches of Celldex Therapeutics/Pfizer's CDX-110 and Merck KGaA's cilengitide will also drive market growth. CDX-110 and cilengitide are being developed for use in newly diagnosed glioma patients and would each be used in combination with Temodar/Temodal. Additionally, overall sales for glioma therapies will be fueled by the launch of AstraZeneca's Recentin, which is in development for relapsed treatment.

"The treatment of glioma, especially the most malignant form--glioblastoma multiforme--is largely ineffective, and the prognosis for these patients is very poor," said Ramya Kollipara, Ph.D. analyst at Decision Resources. "Considerable opportunity remains in this market as currently-approved agents provide only modest improvements in patient outcomes, leaving a high level of unmet need."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources
    Christopher Comfort
    781-296-2597
    ccomfort@dresources.com

    Decision Resources, Inc.
    Elizabeth Marshall
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Panel Says No to Avastin for Advanced Breast Cancer
2. Taxol with avastin produces noteworthy results
3. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
4. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
5. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
6. FDA OKs Avastin for Advanced Breast Cancer
7. Off-Label Avastin Use for Wet Macular Degeneration
8. Avastin Added to Chemo Helps Women With Advanced Cancer
9. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
10. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
11. Another Reason Not to Smoke While Pregnant: Birth Defects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
(Date:2/5/2016)... ... 05, 2016 , ... California Mobile Kitchens , a ... their latest mobile kitchen model, featuring customizable stainless steel interiors and a new, ... for use anywhere in the U.S. Many of their units can be seen ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. ... fixed known bugs within the app. Calls Blacklist allows its users to only have ... of their device’s battery power or memory. It provides a powerful call blocker that ...
(Date:2/5/2016)... ... February 05, 2016 , ... –This week, Atascadero water heater ... having a tankless water heater. To view the report, click here or ... tankless. While each has their pros and cons, the type chosen is almost entirely ...
(Date:2/5/2016)... ... ... is tired of trying to cram belongings into spare space that just isn’t there, a ... but before hastily spending money on a unit, take these tips into consideration. , Self-storage ... is often not told when utilizing these services are some tips on how to use ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest ... is the first of its kind in the ... tattoos through advanced laser treatment. The physician-owned and ... Suncoast by storm with its revitalizing ... and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
(Date:2/4/2016)... IRVINE, Calif. , Feb. 4, 2016  Edwards ... in patient-focused innovations for structural heart disease and critical ... an accelerated share repurchase (ASR) agreement with Morgan Stanley ... common stock.  This repurchase is part of the Company,s ... of the Company,s common stock.  ...
Breaking Medicine Technology: